IndustryCompany release

Transcat second-quarter revenue rises 18% to $97.1M as calibration services grow 23%

🇺🇸 Transcat Inc (TRNS) · Tue 03 Nov 2026

The Nasdaq-listed calibration and test-measurement firm raised its full-year service growth outlook and flagged an August acquisition that extends its hospital biomedical reach.

Transcat reported results for its fiscal second quarter, which ended on 26 September 2026, on 3 November. Total revenue grew 18% to $97.1M, driven mainly by its calibration services business.

Service revenue rose 23% to $64.8M. Service gross margin improved by 220 basis points to 34%. Distribution revenue, the smaller part of the business, increased 10% to $32.3M.

Management raised its full-year outlook for organic service growth to low double digits. The company also noted that it bought Southeastern Biomedical in August, which widens its reach in hospital biomedical calibration.

The summary provided does not include further financial detail, such as profit figures or the precise guidance ranges.

What it means for your team

  • Demand for outsourced calibration looks firm, with service revenue growing faster than product distribution. Quality teams that depend on calibration providers should expect busy service schedules.
  • Calibration underpins data integrity and equipment qualification in GxP-regulated settings, so changes in provider capacity can affect scheduling and audit readiness.
  • The Southeastern Biomedical deal points to continued consolidation in hospital biomedical equipment calibration. Healthcare and device-adjacent quality teams may see changes among their service providers.

Company's press release (SEC filing): Transcat Inc ↗

Article written by VigiEye from the official source (Transcat Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →